Skip to Content

Padcev Side Effects

Generic Name: enfortumab vedotin

Medically reviewed by Last updated on Oct 19, 2020.

Note: This document contains side effect information about enfortumab vedotin. Some of the dosage forms listed on this page may not apply to the brand name Padcev.

For the Consumer

Applies to enfortumab vedotin: parenteral powder for injection

Side effects include:

Fatigue, peripheral neuropathy, decreased appetite, rash, alopecia, nausea, dysgeusia, diarrhea, dry eye, pruritus, dry skin, anemia, lymphopenia, hypophosphatemia, elevated concentrations of lipase, hyperglycemia, hyponatremia, hyperuricemia, neutropenia.

For Healthcare Professionals

Applies to enfortumab vedotin: intravenous powder for injection


Very common (10% or more): Hemoglobin decreased (34%), lymphocytes decreased (32%), neutrophils decreased (14%), leukocytes decreased (14%)[Ref]


Common (1% to 10%): Extravasation (e.g., erythema, swelling, increased temperature, pain), secondary cellulitis, bullae, exfoliation

Frequency not reported: Possible immunogenicity[Ref]


Very common (10% or more): Ocular disorders (e.g., keratitis, blurred vision, limbal stem cell deficiency) (46%), dry eye (e.g., blepharitis, conjunctivitis, dry eye, eye irritation, keratitis, keratopathy, lacrimation increased, limbal stem cell deficiency, Meibomian gland dysfunction, ocular discomfort, punctate keratitis, tear break up time decreased) (36%), blurred vision (14%), dysgeusia (42%)[Ref]


Very common (10% or more): Decreased appetite (52%), phosphate decreased (34%), potassium decreased (19%), lipase increased (14%)

Common (1% to 10%): Glucose increased, sodium decreased, urate increased[Ref]


Very common (10% or more): Fatigue/asthenia (56%)[Ref]


The most common adverse reactions (20% or greater) included fatigue, peripheral neuropathy, decreased appetite, rash, alopecia, nausea, dysgeusia, diarrhea, dry eye, pruritus and dry skin.[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (e.g., hypoesthesia, gait disturbance, muscular weakness, neuralgia, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, peripheral sensorimotor neuropathy) (56%)[Ref]


Very common (10% or more): Creatinine increased (20%)[Ref]


Very common (10% or more): Rash (e.g., dermatitis acneiform, dermatitis contact, dermatitis exfoliative, drug eruption, erythema, erythema multiforme, photosensitivity reaction, rash, rash erythematous, rash generalized, rash macular, rash papular, rash pustular, rash pruritic, rash vesicular, skin exfoliation, stasis dermatitis, urticaria (52%), alopecia (50%), pruritus (30%), maculopapular rash (26%), dry skin (26%), symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) (10%), bullous dermatitis (10%), exfoliative dermatitis (10%), palmar-plantar erythrodysesthesia (10%)[Ref]


Very common (10% or more): Nausea (45%), diarrhea (e.g., colitis, diarrhea, enterocolitis) (42%), vomiting (18%)[Ref]


1. "Product Information. Padcev (enfortumab vedotin)." Seattle Genetics Inc, Bothell, WA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.